|
|
 |
|
Viewing report
|
|
|
|
The Dermatology Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Business Insights, Oct 2008, Pages: 170
The dermatology market remains highly competitive, with developers ranging from Big Pharma to biotechnology and specialty pharmaceutical firms. In recent years levels of innovation in the area have dwindled, allowing generic competition to erode the market share of several leading brands across major drug classes. As leading players continue to lose ground to smaller, specialised players, opportunities are being created for companies that can implement effective lifecycle management and identify lucrative niches.
‘The Dermatology Market Outlook to 2013’ is a new report published by Business Insights that provides comprehensive coverage across key dermatology markets, with analysis of major currently marketed and pipeline drugs. The growth drivers and competitive dynamics of the area are assessed, with revenue and epidemiological forecasts provided for the period 2008-13. This report assesses the 10 leading companies in the dermatology market, examining their product portfolios and R&D pipelines to provide forecasts of their future competitive positions. This report also assesses prevalence rates across the seven major markets in addition to highlighting key trends across the global dermatology area, with coverage of over 95% of the total market.
Discover the key trends and growth drivers of the market for dermatology treatments, assess the competitive dynamics of leading companies and evaluate the future prospects of major products...
Some key findings from this report
- Increased safety concerns will restrict future growth for topical immunosuppressants such as Novartis’ Elidel and Astellas’ Protopic. Both these products have a declining market presence due to the FDA’s black box label warning in 2005 for potential cancer risk.
- Major branded oral acne treatments including Roaccutane will face growing generic competition over the 2008-2013 period. Leading brands in the topical acne treatment market are only expected to achieve marginal growth, while the total market for acne treatments is expected to amass $3b of revenue in 2013.
- The market for psoriasis treatments is forecast to register strong growth between 2008-2013, driven by the performances of key drugs such as Raptiva, Taclonex, Soriatane.
- The corticosteroid market is estimated to value $3.7b by 2013. Reformulated combination corticosteroid/anti-infective brands will continue be integral to the treatment of psoriasis and dermatitis and will continue to be the primary growth drivers within the area.
- Leo Pharma is believed to feature the strongest R&D pipeline in the dermatology market, with five projects currently in the mid to late stages of development. However, most leading companies have sparsely populated pipelines.
Top reasons to order your copy today
- Assess the epidemiology and forecast prevalence of major dermatological disorders including acne, psoriasis, dermatitis, rosacea across key geographies including the UK, Japan, France, Germany, Italy, Spain and the US.
- Evaluate the performances and strategies of major dermatology developers by examining the sales focus by drug class, currently marketed products and R&D portfolios of Bayer Schering, Galderma, GSK, Leo Pharma, Novartis, J&J, Roche, Sanofi-Aventis, Schering-Plough and Stiefel Labs.
- Examine the market dynamics for the global dermatology area and assess key trends and growth drivers across major treatment classes including corticosteroids, topical anti-infectives, acne and psoriasis.
- Forecast revenues for major currently marketed and pipeline dermatology products over 2008-13, with this report’s sales forecasts across major indications, treatment classes and company portfolios.
- Identify the strategies that offer the greatest potential for success in the future, measure the impact of recent key events in the dermatology area and understand the latest issues affecting R&D.
Key issues examined in this report
- Generics threaten branded oral acne treatments. The majority of anti-acne brands, excluding Roaccutane and Diane, are based on generic molecules and formulations. This is expected to cause a shift in developmental focus to topical acne treatments and lead to a collapse in the value of the branded oral acne market.
- The future of corticosteroids. Triple combination products and reformulations are continuing to revive the sales of corticosteroid brands following poor performance in 2006. However, widespread genericization is threatening to stifle future growth in this class.
- Competition intensifies for psoriasis treatments. New molecular entities are largely focused upon psoriasis indications. The market is likely to witness strong growth in the forecast period as anti-TNF therapies such as Enbrel and Humira maintain strong performances.
- Shift in competitive landscape. With large pharma companies apparently neglecting their dermatology pipelines, small specialist players can build a market presence through strong lifecycle management strategies and targeted drug development.
Your questions answered
- What will be the major growth indications and drivers in the dermatology area between 2008-13?
- How will the competitive landscapes for acne, psoriasis, dermatitis, rosacea, viral, bacterial and fungal dermatological infection treatments change by 2013?
- Which companies will become the key players in the dermatology market over the period 2008-2013?
- How have recent launches from companies such as GSK, Galderma and Leo Pharma/Warner Chilcott performed?
- Which pipeline products will be the growth drivers of the future?
- How significant is the threat of generics to the global market?
- What key trends and developments will influence the global dermatology market over 2008-13?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
The Dermatology Market Outlook to 2011
Dermatology - Skin Infections or Dermatosis or Skin Itching Drug Pipeline Report
Psoriasis - Biologics are Yet to Make Topical Treatments Obsolete
Competitive Strategies in Dermatology
Dermatology - Acne Drug Pipeline Report
Dermatology Psoriasis
Advances in Dermatology
The Anti-Infectives Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Clinical Dermatology, 4th Edition
ABC of Dermatology, 5th Edition
Update on Dermatology Market
Commercial Insight: Psoriasis - Intellectual property drives growth
|
|
|
|
